Modality
ERT
MOA
FXIai
Target
BET
Pathway
Lipid Met
SCDCRCAngelman
Development Pipeline
Preclinical
~Aug 2018
→ ~Nov 2019
Phase 1
~Feb 2020
→ ~May 2021
Phase 2
Aug 2021
→ Mar 2031
Phase 2Current
NCT08664586
2,653 pts·CRC
2021-08→2031-03·Active
2,653 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-03-195.0y awayPh2 Data· CRC
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P2
Active
Catalysts
Ph2 Data
2031-03-19 · 5.0y away
CRC
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08664586 | Phase 2 | CRC | Active | 2653 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| NVS-5439 | Novartis | Preclinical | BET | |
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| TAK-8730 | Takeda | Phase 2 | VEGF |